

GENERAL ASSEMBLY OF NORTH CAROLINA  
SESSION 2015

H

D

HOUSE BILL 437\*  
PROPOSED COMMITTEE SUBSTITUTE H437-PCS30309-TK-6

Short Title: Create Permit Exemptions/Home Renal Products.

(Public)

Sponsors:

Referred to:

April 1, 2015

1 A BILL TO BE ENTITLED  
2 AN ACT AMENDING THE PHARMACY PRACTICE ACT TO CREATE A PHARMACY  
3 PERMIT EXEMPTION AND A DEVICE AND MEDICAL EQUIPMENT PERMIT  
4 EXEMPTION FOR THE DISPENSING AND DELIVERY OF HOME RENAL  
5 PRODUCTS AND TO ALLOW FOR DIALYSIS FACILITIES TO BE DESIGNATED AS  
6 AGENTS TO RECEIVE HOME MEDICATIONS FOR PATIENTS WITH RENAL  
7 FAILURE.

8 The General Assembly of North Carolina enacts:

9 SECTION 1. Article 4A of Chapter 90 of the General Statutes is amended by  
10 adding two new sections to read:

11 "**§ 90-85.21C. Pharmacy permit exemption for dispensing and delivery of home renal**  
12 **products.**

13 Each location or facility within or outside this State from which dialysate or drugs  
14 necessary to perform home renal dialysis are dispensed and delivered to a patient in this State is  
15 exempt from the pharmacy permit requirements established by G.S. 90-85.21 and  
16 G.S. 90-8.21A, provided that all the following criteria are met:

- 17 (1) The dialysate or drugs have been approved or cleared by United States Food  
18 and Drug Administration.  
19 (2) The dialysate or drugs are lawfully held by a manufacturer or an agent of the  
20 manufacturer that is properly licensed by the North Carolina Department of  
21 Agriculture and Consumer Services as a manufacturer, or as a wholesaler, or  
22 as both, as required by G.S. 106-145.3.  
23 (3) The dialysate or drugs are held, delivered, and dispensed in their original,  
24 sealed packaging from the manufacturing facility.  
25 (4) The dialysate or drugs are delivered only by the manufacturer, or an agent of  
26 the manufacturer, and only upon receipt of a physician's order.  
27 (5) The manufacturer or an agent of the manufacturer delivers the dialysate or  
28 drugs directly to either of the following:  
29 a. A patient with chronic kidney failure or a designee of the patient, for  
30 self-administration of the dialysis therapy.  
31 b. A health care provider, or health care facility licensed under Chapter  
32 122C, 131D, or 131E of the General Statutes, for administration or  
33 delivery of the dialysis therapy to a patient with chronic kidney  
34 failure.

35 "**§ 90-85.21D. Dialysis facilities as designated agents to receive home medications for**  
36 **patients with renal failure.**



\* H 4 3 7 - P C S 3 0 3 0 9 - T K - 6 \*

1 Pharmacies may ship medications for home use by patients with renal failure to renal  
2 dialysis facilities for delivery to (i) patients who receive dialysis treatments in a Medicare  
3 certified dialysis facility or (ii) patients who self-dialyze at home, provided that all of the  
4 following criteria are met:

- 5 (1) The patient authorizes, in writing, the dialysis facility staff to act as the  
6 patient's designated agent for the purpose of receiving mailed medical  
7 packages at the dialysis facility.
- 8 (2) The pharmacy, whether in-state or out-of-state, is licensed as a pharmacy in  
9 North Carolina.
- 10 (3) The medications for home use are dispensed by the licensed pharmacist  
11 pursuant to a valid prescription order.
- 12 (4) The delivered medication packages are held in a secure location in an area  
13 not accessible to the public and delivered by the dialysis facility staff,  
14 unopened, to the patient.
- 15 (5) Medication packages are individually labeled with the patient name.
- 16 (6) The medications exclude controlled substances, as defined under  
17 G.S. 90-87."

18 **SECTION 2.** G.S. 90-85.22 reads as rewritten:

19 **"§ 90-85.22. Device and medical equipment ~~permits~~permits; exemptions.**

20 ...

21 (c) This section shall not apply to ~~either~~any of the following:

- 22 (1) A pharmaceutical manufacturer registered with the Food and Drug  
23 Administration.
- 24 (2) A wholly owned subsidiary of a pharmaceutical manufacturer registered  
25 with the Food and Drug Administration.
- 26 (3) The dispensing and delivery of home renal products in accordance with the  
27 criteria specified in G.S. 90-85.21C."

28 **SECTION 3.** This act becomes effective October 1, 2015.